1887

Abstract

The erpes zoster is an acute viral illness characterized by a vesicular rash of unilateral distribution, which can eventually cause severe complications, such as post-herpetic neuralgia, ophthalmic zoster, stroke or other neurological complications. In Europe, an incidence of between 2.0 and 4.6 cases per 1000 person-years is estimated, with an increase after 50 years of age. Currently, the therapeutic options for are only partially effective in limiting the acute phase, while the management of complications is frequently complex and not satisfactory. The overall burden of the disease and the elevated costs associated with diagnosis and clinical and therapeutic management led to the development of a new preventive approach through a live attenuated virus vaccine. The vaccine now available decreases the incidence of the disease, post-herpetic neuralgia and the burden of illness. Moreover, the vaccine is safe and well tolerated and it seems to confer long-term protection. Based on the clinical results and evidence provided by the Health Technology Assessment, several countries introduced immunization although with different recommendations and methods of funding.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000386
2016-12-16
2020-01-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/12/1363.html?itemId=/content/journal/jmm/10.1099/jmm.0.000386&mimeType=html&fmt=ahah

References

  1. Bonanni P., Azzari C., Castiglia P., Chiamenti G., Conforti G., Conversano M., Corsello G., Ferrera G., Ferro A. et al. 2014; [The 2014 lifetime immunization schedule approved by the Italian scientific societies. Italian Society of Hygiene, Preventive Medicine, and Public Health. Italian Society of Pediatrics. Italian Federation of Pediatric Physicians. Italian Federation of General Medical Physicians. Arezzo Service of Legal Medicine]. Epidemiol Prev38:131–146[PubMed]
    [Google Scholar]
  2. Bricout H., Perinetti E., Marchettini P., Ragni P., Zotti C. M., Gabutti G., Volpi A., Franco E.. 2014; Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort study. BMC Infect Dis14:637 [CrossRef][PubMed]
    [Google Scholar]
  3. Calabria Region 2015; Improvement of vaccination coverage in different age groups. Available athttp://www.regione.calabria.it/sanita/allegati/dca_2015/dca_n._43_del_21.05.2015_-_copertura_vaccinale.pdf Accessed: 4 July 2016
  4. Coretti S., Ruggeri M., Codella P.. 2014; Cost effectiveness analysis of a vaccine to prevent herpes zoster and postherpetic neuralgia in Italy. Value Health17:A511 [CrossRef][PubMed]
    [Google Scholar]
  5. Donahue J. G., Choo P. W., Manson J. E., Platt R.. 1995; The incidence of herpes zoster. Arch Intern Med155:1605 [CrossRef][PubMed]
    [Google Scholar]
  6. Dworkin R. H., Gnann J. W., Oaklander A. L., Raja S. N., Schmader K. E., Whitley R. J.. 2008; Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain9:37–44 [CrossRef]
    [Google Scholar]
  7. EUnetHTA 2013; Pilot of rapid assessment on ‘Zostavax for the prevention herpes zoster’. Available athttp://www.eunethta.eu/news/pilot-rapid-assessment-zostavax-prevention-herpes-zoster-available Accessed: 4 July 2016
  8. Fashner J., Bell A. L.. 2011; Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician83:1432–1437[PubMed]
    [Google Scholar]
  9. Friuli Venezia Giulia Region 2014; Regional Council resolution n. 2535 ‘Upgrading and extension of the immunization offer in the Friuli Venezia Giulia Region’. Available athttp://mtom.regione.fvg.it/storage/2014_2535/Testo%20integrale%20della%20Delibera%20n%202535-2014.pdf Accessed: 4 July 2016
  10. Gabutti G., Serenelli C., Sarno O., Marconi S., Corazza M., Virgili A.. 2010; Epidemiologic features of patients affected by herpes zoster: database analysis of the Ferrara University Dermatology Unit, Italy. Med Mal Infect40:268–272 [CrossRef][PubMed]
    [Google Scholar]
  11. Gershon A. A., Gershon M. D., Breuer J., Levin M. J., Oaklander A. L., Griffiths P. D.. 2010; Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol48:S2–S7 [CrossRef][PubMed]
    [Google Scholar]
  12. Gialloreti L. E., Merito M., Pezzotti P., Naldi L., Gatti A., Beillat M., Serradell L., di Marzo R., Volpi A.. 2010; Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis10:230 [CrossRef][PubMed]
    [Google Scholar]
  13. Gross G., Schöfer H., Wassilew S., Friese K., Timm A., Guthoff R., Pau H. W., Malin J. P., Wutzler P., Doerr H. W.. 2003; Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol26:277–289[PubMed]
    [Google Scholar]
  14. Harpaz R., Ortega-Sanchez I. R., Seward J. F.. 2008; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep57:1–30
    [Google Scholar]
  15. HCSP (Haut Conseil de la Santé Publique) report 2013; Available athttp://39.HCSP report, available athttp://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=390 (Accessed: 4 July 2016)
  16. Irwin M., Costlow C., Williams H., Artin K. H., Chan C. Y., Stinson D. L., Levin M. J., Hayward A. R., Oxman M. N.. 1998; Cellular immunity to varicella-zoster virus in patients with major depression. J Infect Dis178:S104–S108 [CrossRef][PubMed]
    [Google Scholar]
  17. Johnson R. W., Whitton T. L.. 2004; Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother5:551–559 [CrossRef][PubMed]
    [Google Scholar]
  18. Johnson R. W.. 2007; Zoster-associated pain: what is known, who is at risk and how can it be managed?. Herpes14:30–34[PubMed]
    [Google Scholar]
  19. Johnson R. W., Wasner G., Saddier P., Baron R.. 2007; Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother7:1581–1595 [CrossRef]
    [Google Scholar]
  20. Johnson R. W., Bouhassira D., Kassianos G., Leplège A., Schmader K. E., Weinke T.. 2010; The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med8:37 [CrossRef][PubMed]
    [Google Scholar]
  21. Katz J., Cooper E. M., Walther R. R., Sweeney E. W., Dworkin R. H.. 2004; Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis39:342–348 [CrossRef][PubMed]
    [Google Scholar]
  22. Langan S. M., Smeeth L., Margolis D. J., Thomas S. L.. 2013; Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med10:e1001420 [CrossRef][PubMed]
    [Google Scholar]
  23. Levin M. J., Smith J. G., Kaufhold R. M., Barber D., Hayward A. R., Chan C. Y., Chan I. S., Li D. J., Wang W. et al. 2003; Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis188:1336–1344 [CrossRef][PubMed]
    [Google Scholar]
  24. Liguria Region 2014; Update Regional Prevention Plan. Available athttp://www.asl5.liguria.it/Portals/0/Comunicati/20150409_piano%20regionale%20vaccini%20liguria%202014.pdf Accessed: 4 July 2016
  25. Lu P. J., Euler G. L., Harpaz R.. 2011; Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med40:e1–e6 [CrossRef][PubMed]
    [Google Scholar]
  26. Lukas K., Edte A., Bertrand I.. 2012; The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss20:441–451 [CrossRef][PubMed]
    [Google Scholar]
  27. Marin M., Yawn B. P., Hales C. M., Wollan P. C., Bialek S. R., Zhang J., Kurland M. J., Harpaz R.. 2015; Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother11:1157–1164 [CrossRef][PubMed]
    [Google Scholar]
  28. Molise Region 2015; Regional immunization offering 2015-2016. Available athttp://www3.regione.molise.it/flex/cm/pages/ServeAttachment.php/L/IT/D/5%252Fc%252F1%252FD.5cf3a1ec54145aa197e0/P/BLOB%3AID%3D13619/E/pdf Accessed: 4 July 2016
  29. Morrison V. A., Johnson G. R., Schmader K. E., Levin M. J., Zhang J. H., Looney D. J., Betts R., Gelb L., Guatelli J. C. et al. 2015; Long-term persistence of zoster vaccine efficacy. Clin Infect Dis60:900–909 [CrossRef][PubMed]
    [Google Scholar]
  30. Murray A. V., Reisinger K. S., Kerzner B., Stek J. E., Sausser T. A., Xu J., Wang W. W., Chan I. S., Annunziato P. W., Parrino J.. 2011; Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin7:1130–1136 [CrossRef][PubMed]
    [Google Scholar]
  31. Okamoto S., Hata A., Sadaoka K., Yamanishi K., Mori Y.. 2009; Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis200:1606–1610 [CrossRef][PubMed]
    [Google Scholar]
  32. Opstelten W., Zaal M. J.. 2005; Managing ophthalmic herpes zoster in primary care. BMJ331:147–151 [CrossRef][PubMed]
    [Google Scholar]
  33. Oxman M. N.. 1995; Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology45:S41–S46 [CrossRef][PubMed]
    [Google Scholar]
  34. Oxman M. N., Levin M. J., Johnson G. R., Schmader K. E., Straus S. E., Gelb L. D., Arbeit R. D., Simberkoff M. S., Gershon A. A. et al. 2005; A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med352:2271–2284 [CrossRef][PubMed]
    [Google Scholar]
  35. Pinchinat S., Cebrián-Cuenca A. M., Bricout H., Johnson R. W.. 2013; Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis13:170 [CrossRef][PubMed]
    [Google Scholar]
  36. Public Health England 2013; Herpes zoster (shingles) immunisation programme 2013/2014: Report for England. Available athttps://www. gov.uk/government/uploads/system/uploads/attachment_data/file/383018/ShinglesReport2014.pdf Accessed: 4 July 2016
  37. Schmader K.. 2001; Herpes zoster in older adults. Clin Infect Dis32:1481–1486 [CrossRef][PubMed]
    [Google Scholar]
  38. Schmader K. E., Levin M. J., Gnann J. W., McNeil S. A., Vesikari T., Betts R. F., Keay S., Stek J. E., Bundick N. D. et al. 2012a; Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis54:922–928 [CrossRef]
    [Google Scholar]
  39. Schmader K. E., Oxman M. N., Levin M. J., Johnson G., Zhang J. H., Betts R., Morrison V. A., Gelb L., Guatelli J. C. et al. 2012b; Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis55:1320–1328 [CrossRef]
    [Google Scholar]
  40. Sicily Region 2015; Amending and supplementing the immunization schedule for Life. D.A. n° 38/2015. Available athttp://pti.regione.sicilia.it/portal/page/portal/PIR_PORTALE/PIR_LaStrutturaRegionale/PIR_AssessoratoSalute/PIR_Decreti/PIR_Decreti2015/PIR_Decretiassessorialianno2015/12%2001%202015%20SERV%201%20(38).pdf Accessed on 4 July 2016
  41. Tseng H. F., Tartof S., Harpaz R., Luo Y., Sy L. S., Hetcher R. C., Jacobsen S. J.. 2014; Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis59:913–919 [CrossRef][PubMed]
    [Google Scholar]
  42. Veneto Region 2014; Approval of the new immunization schedule of Veneto Region. Regional Council Deliberation n. 1564 in Regional Official Bulletin n. 89 of 12 September 2014
  43. Volpi A.. 2007; Severe complications of herpes zoster. Herpes14:35–39[PubMed]
    [Google Scholar]
  44. Yawn B. P., Saddier P., Wollan P. C., St Sauver J. L., Kurland M. J., Sy L. S.. 2007; A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc82:1341–1349 [CrossRef][PubMed]
    [Google Scholar]
  45. Yawn B. P., Gilden D.. 2013; The global epidemiology of herpes zoster. Neurology81:928–930 [CrossRef][PubMed]
    [Google Scholar]
  46. Zhang J., Xie F., Delzell E., Chen L., Winthrop K. L., Lewis J. D., Saag K. G., Baddley J. W., Curtis J. R.. 2012; Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA308:43–49 [CrossRef][PubMed]
    [Google Scholar]
  47. Zostavax SPC Zostavax® 2016; Summary of Product Characteristics. Annex I. Available athttp://ec.europa.eu/health/documents/community-register/2006/2006051911419/anx_11419_it.pdf Accessed on 4 July 2016
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000386
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error